All News

In honor of World Diabetes Day, AstraZeneca has launched the campaign Diabetes Can Break Your Heart, the national movement aimed to change the trajectory of heart failure in type 2 diabetes.

Centers for Disease Control and Prevention warns the time for action is now in the "post-antibiotic era."

Receiving a flu shot before a heart bypass surgery can stop inflammation throughout the body and possibly lead to a healthier recovery, according to a preliminary study presented at the American Heart Association’s Scientific Sessions in Philadelphia, Pennsylvania.

The COAST-X study evaluated ixekizumab (Taltz, Eli Lilly) in patients with non-radiographic axial spondyloarthritis.

A study presented at the 2019 ACR/ARP Annual Meeting highlights the need for additional medications for the treatment of juvenile idiopathic arthritis in children.

With vincristine in short supply, Teva will resume production of the chemotherapy agent following its previous decision to remove the product from the market.

The largest study of its kind has found that 40% of the European population carries a genetic variant that leads to antibody resistance against anti-tumor necrosis factor (TNF) drugs, infliximab and adalimumab, and lose response.

Alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, was compared with a placebo in patients with ACS and persistent dyslipidemia, in addition to receiving treatment with high-intensity or maximum tolerated statin therapy.

A study reveals that axial psoriatic arthritis and ankylosing spondylitis with psoriasis are different diseases with different genetics, demographics, and disease expression.

The online resource features CBD products that have been tested for concentrations of all cannabinoids, including CBD and tetrahydrocannabinol (THC), by an independent, third-party lab, as well as experts that pharmacists can contact with questions regarding buying, selling, and marketing.

A study conducted by the Uniting Medically Supervised Injecting Centre in Sydney, Australia found that intranasally administered naloxone can reverse opioid overdose, but not as efficiently as intramuscularly administered naloxone can.

Findings from a phase 3 study reinforced the safety and efficacy of rituximab (Rituxan, Genentech) as a treatment for patients with pemphigus vulgaris.

The injectable hormone tesamorelin was found to reduce liver fat and prevent liver fibrosis or scarring in people living with HIV, according to researchers and the National Institutes of Health and the National Institute of Allergy and Infectious Disease (NIAD).

Top news of the day from across the health care landscape.

A recent study published in CANCER indicates that for patients with both HIV and cancer, implementation of the Patient Protection and Affordable Care Act (ACA) improved insurance coverage, both in states that expanded Medicaid coverage and in states that did not.1

InsightRx, a company specializing in precision medicine, and Premier Inc, a health care improvement company, have partnered to individualize medication dosing for drugs used to treat infectious diseases.

Jesse C. Dresser, Esq explains how DIR fees affect specialty pharmacists at the NASP Annual Meeting in Washington, DC.

Weight loss surgery found to cut the overall risk of developing cancers linked to obesity by 20%.

Neuromyelitis optica is the fourth chronic disease that hematopoietic stem cell transplantation has appeared to reverse.

IVIG found to have a good safety profile in pediatric patients, with low risk of severe adverse drug reactions.

Survivors of long-term diffuse large B-cell lymphoma found to have a higher risk of developing a second primary cancer.

Top news of the day from across the health care landscape.

Annual Award Celebrates Electronic Health Records, Health Systems and Pharmacy Industry Leaders for Improving Patient Safety and Workflow Efficiency

A study looked at the incidence of thrombosis in patients being treated with ibrutinib for hematologic malignancies.

What is causing a positive drug test in a patient that only takes blood pressure medications?

We want to hear from you!

FDA breakthrough designation is based on data for nivolumab plus ipilimumab in a study evaluating the immuno-oncology combination in patients with advanced hepatocellular carcinoma previously treated with sorafenib.

Oligodendrocyte progenitor cells were often ignored by scientists studying multiple sclerosis; however, new research shows that they are critical in its production.